Trillium reports Phase I data for TTI-621 in DLBCL

Trillium Therapeutics Inc. (TSX:TRIL; NASDAQ:TRIL) reported data from 18 evaluable patients with diffuse large B cell lymphoma (DLBCL) in the dose-expansion

Read the full 215 word article

User Sign In